Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Poseida Therapeutics

Main focus: CAR-T cell therapies and liver-directed gene-editing therapies

Company stage: Clinical

Diseases: B-cell, multiple myeloma and solid cancers

Genome editing technology: Cas-CLOVER

Funding stage: Public (NASDAQ:PSTX)

Location: San Diego, CA, USA

Website: https://poseida.com/

Pipeline: https://poseida.com/science/pipeline/

Partnerships: Takeda Pharmaceuticals

Poseida Therapeutics is a clinical-stage CAR-T and gene editing company. The company is focused on treating various cancer types such as multiple myeloma, prostate cancer and B-cell malignancies. Poseida uses a proprietary gene-editing technology known as Cas-CLOVER in order to induce multiple edits in the genomes of its CAR-T cell products.

Poseida Therapeutics

Tags

News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases